

MGFA Registry & Real-World Data Research Funding Opportunity

Summer 2026 Request for Applications (RFA)

Myasthenia Gravis Foundation of America

Overview

The Myasthenia Gravis Foundation of America (MGFA) is pleased to announce the MGFA Registry & Real-World Data Research Funding Opportunity, a competitive award program designed to accelerate high-impact research, abstract development, and peer-reviewed publications that improve the lives of individuals living with myasthenia gravis (MG) and related neuromuscular junction disorders.

Through this initiative, MGFA will support investigators seeking to leverage unique patient-reported, longitudinal, and real-world clinical datasets to generate meaningful scientific insights that advance the field. Applicants may propose projects using one or more of three available datasets, subject to feasibility and data governance approval.

MGFA intends to fund four (4) meritorious awards of up to \$10,000 each to support approved data extraction, analytics, statistical programming, and related research activities. This opportunity is intended to expand access to valuable MG datasets while fostering the next generation of clinical investigators and scientific leaders.

Award at a Glance

| | |
|----------------------------|---|
| Number of Awards | 4 meritorious awards |
| Award Amount | Up to \$10,000 USD per award |
| Eligible Uses | Data extraction, analytics, statistical programming, vendor pass-through costs |
| Indirect Costs | Not permitted |
| Project Period | 6 months |
| Eligible Applicants | Academic investigators — fellows, residents, junior faculty, established investigators, international researchers |

Available Datasets

Applicants may propose projects using one or more of the following datasets. Each dataset has distinct characteristics, geographic scope, and data elements. Investigators are encouraged to review the dataset summary carefully and select the source(s) best aligned with their proposed research question. Multi-dataset proposals are welcome.

| Feature | MyRealWorld MG | Vitaccess Real MG Registry |
|------------------------|---|--|
| Data Type | Patient-reported outcomes (longitudinal) | Hybrid: patient-reported + clinical record data |
| Status | Completed study (2019–2024) | Active registry (since Sept 2024) |
| Participants | 2,018 participants across 10 countries | 187 participants (US and UK; growing) |
| Geography | Italy, US, Spain, Japan, Germany, UK, France, Denmark, Canada, Belgium | United States, United Kingdom |
| Key Measures | MG-ADL, MG-QoL-15r, EQ-5D-5L, HADS, FACIT-Fatigue, PROMIS, HUI3, treatment use, healthcare utilization, work impact | MG-ADL (clinician + patient), MG-QoL-15r, MG Fatigue Scale, NeuroQoL Fatigue, clinical characteristics (eCRF), medication logs, HCRU, adverse events |
| Unique Strength | Large multinational longitudinal PRO dataset; anxiety/depression, fatigue, QoL trajectories over time | Dual patient + clinician data source; enables modern observational and comparative effectiveness research |

1. MyRealWorld MG Dataset

A completed multinational longitudinal observational study conducted between December 2019 and May 2024, with over 2,000 participants across 10 countries. The study collected patient-reported outcomes at regular intervals, including validated measures of health-related quality of life, anxiety and depression, fatigue, functional status, and healthcare utilization. Key instruments include:

- MG-ADL and MG-QoL-15r (MG-specific outcomes)
- EQ-5D-5L with bolt-on items (generic HRQoL)
- Hospital Anxiety and Depression Scale (HADS)
- FACIT-Fatigue and PROMIS Sleep Disturbance*
- Health Utilities Index III (HUI3)
- Treatment use, healthcare visits, and work/study impact

Countries represented include Italy (n=763), United States (n=633), Spain (n=204), Japan (n=129), Germany (n=114), the United Kingdom (n=63), and others. This dataset is particularly suited for cross-national comparisons, longitudinal trajectory analyses, and studies of fatigue, depression, and quality of life over time.

*These surveys were optional, patient numbers may be more limited for these instruments.

2. Vitaccess Real MG Registry

An active hybrid real-world registry combining patient-reported outcomes with structured clinical data and medical record inputs via electronic case report forms (eCRF) completed by healthcare

professionals or captured through electronic medical record (EMR) aggregators. The registry has been active since September 2024, with current enrollment of 187 participants in the United States and United Kingdom. Key data elements include:

- Clinical characteristics: diagnosis, antibody status, MGFA class, thymus involvement
- Comprehensive medical history and comorbidity data
- Routine and rescue MG medication logs (dose, frequency, start/stop, reason for switching)
- MG-ADL (clinician-administered and patient-reported versions)
- MG-QoL-15r, MG Symptom PRO Fatigue Scale, and NeuroQoL Fatigue Short Form
- Healthcare resource utilization and adverse event tracking

The Vitaccess Real MG Registry is uniquely suited for research requiring both clinician-confirmed clinical data and longitudinal patient-reported outcomes. Investigators are encouraged to consider the growing but currently smaller sample size when scoping their proposed analyses.

Research Priorities

MGFA welcomes proposals aligned with its scientific mission. The Research Committee has identified the following priority areas of unmet need; proposals addressing one or more of these areas are especially encouraged.

- **Biomarkers**
 - Early diagnosis
 - Predictors of clinical outcome
 - Predictors of treatment response
 - Biomarkers relevant to clinical trials
- **Mechanisms of Disease**
 - Disease progression
 - Sustained loss of self-tolerance
 - Phenotypic variation
- **Therapeutic Strategies**
 - Optimization of current therapies
 - New therapeutic targets
 - Real-world treatment sequencing and switching patterns
 - Safety and tolerability
- **Improving Patient Outcomes**
 - Patient perspective and treatment priorities
 - Quality of life
 - Fatigue burden
 - Functional outcomes
 - Healthcare access and financial toxicity
 - Caregiver burden and health disparities
- **Transitional Care**
 - Long-term outcomes and safety considerations

Projects outside these themes will also be considered if scientifically compelling and aligned with MGFA's mission. The Research Committee recognizes that not all priority areas may be fully captured in every dataset and is committed to supporting the best science.

Suggested Research Topics

The following examples are intended to illustrate the range of research questions that could be pursued using the available datasets:

- Predictors of poor quality of life despite controlled symptoms
- Real-world corticosteroid burden in MG
- Fatigue trajectories over time
- Differences in outcomes across countries or healthcare systems
- Treatment discontinuation and switching patterns
- Impact of MG on work productivity
- MG-ADL or MG-QoL trends over time
- Comparative effectiveness of treatments versus standard of care, or comparison of a specific treatment versus a treatment class.
- Anxiety and depression as comorbidities in MG: prevalence and impact

Eligibility

Applications are encouraged from across the academic spectrum, including:

- Academic faculty investigators (junior and established)
- Fellows and residents
- Early-stage investigators
- International academic researchers

Applications are not open to for-profit commercial entities or small businesses as lead applicants. Collaborative multidisciplinary teams are strongly encouraged.

Application Components

All materials are to be submitted through MGFA's designated grants portal. The complete application consists of the following:

Required Materials

- **Research Proposal (3–5 pages recommended)**
 - Background and scientific rationale
 - Objective / hypothesis
 - Dataset(s) requested and justification for selection
 - Study design
 - Variables of interest
 - Statistical approach
 - Deliverables and publication target
- **Lay Summary (250 words maximum)**
- **Curriculum Vitae or NIH Biosketch**
- **Timeline and Milestones**

Optional Materials

- Letter of Support

Review Criteria

Applications will be reviewed competitively by the MGFA Research Committee based on the following criteria:

- Scientific merit and rigor
- Feasibility using the available dataset(s)
- Innovation and significance to the field
- Relevance to the MGFA mission and research priorities
- Publication potential and dissemination plan
- Investigator qualifications and readiness
- Value to patients and clinicians

Priority may be given to proposals with high likelihood of generating abstracts, manuscripts, or actionable insights within 12 months of the award start date.

Key Dates

| Activity | Date |
|--------------------------|-------------------------------------|
| RFA Launch | June 12, 2026 |
| Application Opens | June 12, 2026 |
| Submission Deadline | July 31, 2026 |
| Scientific Review Period | August 10, 2026 – September 4, 2026 |
| Award Notifications | September 16, 2026 |
| Project Start Date | October 1, 2026 |

Awardee Expectations

Recipients of this award will be expected to fulfill the following obligations:

- Acknowledge MGFA support in all resulting abstracts, presentations, posters, and publications using MGFA-provided acknowledgment language.
- Provide copies of submitted abstracts and manuscripts to MGFA
- Submit a manuscript for publication, consistent with ICMJE policy, within 6 months of award acceptance
- Submit a written lay summary and lay-oriented presentation within 6 months of award acceptance

- Provide copies of submitted abstracts, posters, oral presentations, and manuscripts to MGFA on an ongoing basis as materials become available.

MGFA may invite awardees to present findings at future scientific or community forums, including the MGFA Scientific Session at the AANEM Annual Meeting and the MGFA National Conference.

Strategic Goal

MGFA seeks to unlock the value of high-quality real-world MG data to:

- Accelerate evidence generation in MG
- Improve patient outcomes through data-driven insights
- Strengthen the MG research ecosystem
- Support rising investigators at all career stages
- Drive publishable, practice-informing science

Questions and Contacts

Scientific or Programmatic Inquiries

For inquiries related to the MGFA, this proposal, or similar; please email

Melissa Jenkins, MS

mjenkins@myasthenia.org

Grants Portal Technical Support

Contacts for Questions

For technical inquiries such as system access or site navigation related to ProposalCentral, please email pcsupport@altum.com or call 1-800-875-2562 (toll-free US and Canada) or +1-703-964.5840 (Direct Dial International).

More information about how to register and apply using ProposalCentral:

- [How to Register as a ProposalCentral user](#)
- [How to Create an Application using ProposalCentral](#)
- [User FAQs.pdf \(proposalcentral.com\)](#)

MGFA looks forward to partnering with investigators worldwide to transform real-world data into meaningful discoveries for the MG community.

Myasthenia Gravis Foundation of America • mgfa@myasthenia.org